A functional assay to identify amyloidogenic light chains

Emily Martin, Angela D. Williams, Robert Heidel, James S. Foster, Ronald Lands, Stephen Kennel, Jonathan Wall

Research output: Contribution to journalArticle

Abstract

Introduction: Multiple myeloma (MM) and light chain monoclonal gammopathy of undetermined significance (LCMGUS) are plasma cell disorders associated with the secretion of monoclonal free light-chain (LC) proteins. Due to the high concentrations of LC in circulation, both of these populations are at risk for developing LC-associated amyloidosis (AL)–a protein misfolding disease characterized by the deposition of LC protein fibrils in organs and tissues, leading to dysfunction and significant morbidity. At present, accurate identification of subjects at risk for developing amyloidosis is not possible, but with the advent of novel, amyloid-targeted therapies, identification of pre-symptomatic individuals is of clinical import. Methods: To address this, a competition assay has been developed to discern LC proteins with enhanced amyloidogenic potential. Numerous factors that may influence the efficacy of the assay have been evaluated to yield optimal conditions. Results: Using a panel of nine patient-derived LC, we have demonstrated that amyloid-associated LC inhibited the recruitment of a biotinyl-λ6 variable domain by homologous amyloid-like fibrils significantly more than MM LC (p <.01). Conclusion: The assay accurately discriminated AL from MM patient populations, suggesting that it may aid in the identification of patients with monoclonal gammopathies who have an increased risk of developing amyloidosis.

Original languageEnglish (US)
Pages (from-to)93-100
Number of pages8
JournalAmyloid
Volume25
Issue number2
DOIs
StatePublished - Apr 3 2018

Fingerprint

Light
Amyloidosis
Multiple Myeloma
Amyloid
Proteostasis Deficiencies
Monoclonal Gammopathy of Undetermined Significance
Paraproteinemias
Proteins
Plasma Cells
Morbidity
Population

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

A functional assay to identify amyloidogenic light chains. / Martin, Emily; Williams, Angela D.; Heidel, Robert; Foster, James S.; Lands, Ronald; Kennel, Stephen; Wall, Jonathan.

In: Amyloid, Vol. 25, No. 2, 03.04.2018, p. 93-100.

Research output: Contribution to journalArticle

@article{d4d84d0e1b1344c59c312ed7238ca0a2,
title = "A functional assay to identify amyloidogenic light chains",
abstract = "Introduction: Multiple myeloma (MM) and light chain monoclonal gammopathy of undetermined significance (LCMGUS) are plasma cell disorders associated with the secretion of monoclonal free light-chain (LC) proteins. Due to the high concentrations of LC in circulation, both of these populations are at risk for developing LC-associated amyloidosis (AL)–a protein misfolding disease characterized by the deposition of LC protein fibrils in organs and tissues, leading to dysfunction and significant morbidity. At present, accurate identification of subjects at risk for developing amyloidosis is not possible, but with the advent of novel, amyloid-targeted therapies, identification of pre-symptomatic individuals is of clinical import. Methods: To address this, a competition assay has been developed to discern LC proteins with enhanced amyloidogenic potential. Numerous factors that may influence the efficacy of the assay have been evaluated to yield optimal conditions. Results: Using a panel of nine patient-derived LC, we have demonstrated that amyloid-associated LC inhibited the recruitment of a biotinyl-λ6 variable domain by homologous amyloid-like fibrils significantly more than MM LC (p <.01). Conclusion: The assay accurately discriminated AL from MM patient populations, suggesting that it may aid in the identification of patients with monoclonal gammopathies who have an increased risk of developing amyloidosis.",
author = "Emily Martin and Williams, {Angela D.} and Robert Heidel and Foster, {James S.} and Ronald Lands and Stephen Kennel and Jonathan Wall",
year = "2018",
month = "4",
day = "3",
doi = "10.1080/13506129.2018.1456425",
language = "English (US)",
volume = "25",
pages = "93--100",
journal = "Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis",
issn = "1350-6129",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - A functional assay to identify amyloidogenic light chains

AU - Martin, Emily

AU - Williams, Angela D.

AU - Heidel, Robert

AU - Foster, James S.

AU - Lands, Ronald

AU - Kennel, Stephen

AU - Wall, Jonathan

PY - 2018/4/3

Y1 - 2018/4/3

N2 - Introduction: Multiple myeloma (MM) and light chain monoclonal gammopathy of undetermined significance (LCMGUS) are plasma cell disorders associated with the secretion of monoclonal free light-chain (LC) proteins. Due to the high concentrations of LC in circulation, both of these populations are at risk for developing LC-associated amyloidosis (AL)–a protein misfolding disease characterized by the deposition of LC protein fibrils in organs and tissues, leading to dysfunction and significant morbidity. At present, accurate identification of subjects at risk for developing amyloidosis is not possible, but with the advent of novel, amyloid-targeted therapies, identification of pre-symptomatic individuals is of clinical import. Methods: To address this, a competition assay has been developed to discern LC proteins with enhanced amyloidogenic potential. Numerous factors that may influence the efficacy of the assay have been evaluated to yield optimal conditions. Results: Using a panel of nine patient-derived LC, we have demonstrated that amyloid-associated LC inhibited the recruitment of a biotinyl-λ6 variable domain by homologous amyloid-like fibrils significantly more than MM LC (p <.01). Conclusion: The assay accurately discriminated AL from MM patient populations, suggesting that it may aid in the identification of patients with monoclonal gammopathies who have an increased risk of developing amyloidosis.

AB - Introduction: Multiple myeloma (MM) and light chain monoclonal gammopathy of undetermined significance (LCMGUS) are plasma cell disorders associated with the secretion of monoclonal free light-chain (LC) proteins. Due to the high concentrations of LC in circulation, both of these populations are at risk for developing LC-associated amyloidosis (AL)–a protein misfolding disease characterized by the deposition of LC protein fibrils in organs and tissues, leading to dysfunction and significant morbidity. At present, accurate identification of subjects at risk for developing amyloidosis is not possible, but with the advent of novel, amyloid-targeted therapies, identification of pre-symptomatic individuals is of clinical import. Methods: To address this, a competition assay has been developed to discern LC proteins with enhanced amyloidogenic potential. Numerous factors that may influence the efficacy of the assay have been evaluated to yield optimal conditions. Results: Using a panel of nine patient-derived LC, we have demonstrated that amyloid-associated LC inhibited the recruitment of a biotinyl-λ6 variable domain by homologous amyloid-like fibrils significantly more than MM LC (p <.01). Conclusion: The assay accurately discriminated AL from MM patient populations, suggesting that it may aid in the identification of patients with monoclonal gammopathies who have an increased risk of developing amyloidosis.

UR - http://www.scopus.com/inward/record.url?scp=85044346676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044346676&partnerID=8YFLogxK

U2 - 10.1080/13506129.2018.1456425

DO - 10.1080/13506129.2018.1456425

M3 - Article

VL - 25

SP - 93

EP - 100

JO - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

JF - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

SN - 1350-6129

IS - 2

ER -